Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kailera Therapeutics' SEC filings document its public-company formation, capital structure, and governance framework following its initial public offering. The company's Form 8-K records the filing of an amended and restated certificate of incorporation, the registration of KLRA common stock on the Nasdaq Global Select Market, and its status as an emerging growth company.
The filing record identifies authorized common stock, undesignated preferred stock authority, Delaware corporate governance matters, and securities registered under Section 12(b) of the Exchange Act. These disclosures provide the formal regulatory record for Kailera's transition into a Nasdaq-listed clinical-stage biotechnology issuer.
Kailera Therapeutics, Inc. director Liu Yuting filed an initial Form 3, which is a statement of beneficial ownership by an insider. The filing shows no reported transactions, no derivative positions, and no buy, sell, acquire, or dispose activity in the securities of Kailera Therapeutics at this time.
Kailera Therapeutics, Inc. reported the initial equity holdings of Chief People Officer Paula Cloghessy on a Form 3, showing multiple stock option awards to purchase common stock. These options give her the right to buy shares at exercise prices between $5.25 and $7.24 per share.
The holdings include options over 230,728 underlying shares at an exercise price of $7.24 expiring in 2035, 95,350 shares at $5.40 expiring in 2035, and two grants of 86,150 and 128,388 shares at $5.25 expiring in 2034. Footnotes state each grant vests 25% on specified initial vesting dates in 2025 or 2026, then in 36 substantially equal monthly installments, subject to her continued service.
Kailera Therapeutics, Inc. director, CEO and President Ronald C. Renaud Jr. reports holdings of multiple stock options to buy Common Stock. These options cover blocks of underlying shares at exercise prices of $7.2400 and $5.2500 per share with expiration dates in 2034 and 2035.
Footnotes state that certain options are already fully vested, while others vest over time, typically with 33% or 25% vesting on an initial date and the remainder in substantially equal monthly installments, subject to his continued service.
Kailera Therapeutics director Frank Clyburn reports holding a stock option covering 170,194 shares of common stock at an exercise price of $7.24 per share. The option expires on November 5, 2035 and vests 25% on October 31, 2026, then in 36 substantially equal monthly installments.
Kailera Therapeutics, Inc. disclosed the stock option holdings of its Chief Legal Officer, Scott Akamine. He holds options to buy 193,999 shares of common stock at an exercise price of $7.24 per share, expiring on November 5, 2035.
He also holds options tied to 143,673 and 213,890 underlying shares at an exercise price of $5.25 per share, both expiring on December 9, 2034. These options vest 25% on specified initial vesting dates, then in 36 monthly installments, subject to his continued service with the company.